Antibiotic treatment for a rare pneumonia in ICU patients
Part of Infections, Lungs & breathing clinical trials.
This study looks at how well antibiotics work for pneumonia caused by a specific bacterium (Stenotrophomonas maltophilia) in patients who are on breathing machines in the intensive care unit (ICU). It will help doctors choose the best treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You were in the medical ICU anytime from January 2018 to December 2023.
- You needed a breathing tube and machine (ventilator) to help you breathe.
- You had pneumonia from a bacterium called Stenotrophomonas maltophilia while on the ventilator.
- You have not refused to allow your medical data to be used for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at how well doctors followed current guidelines to diagnose ventilator-associated pneumonia (a lung infection from a breathing tube) in ICU patients between 2022 and 2024. It aims to improve future care.
This study tests whether using a DNA test on lung fluid can help doctors choose better antibiotics for pneumonia in ICU patients with weakened immune systems. It may lead to more effective treatment and fewer side effects.
This trial tests an “antibiotic stewardship” approach—choosing and adjusting antibiotics in a smarter way—for a first episode of pneumonia in patients on a breathing machine. It may help ensure the right antibiotics are used at the right time, while avoiding unnecessary or overly broad treatment.
This trial is testing a new way to choose antibiotics for people with COPD who get pneumonia and need intensive care. The goal is to find the best treatment using a personalized approach.
This study looks at different types of lung infections in ICU patients on breathing machines. By analyzing fluid from your lungs, researchers hope to better understand pneumonia and improve treatment.
This study tests whether giving inhaled antibiotics based on a patient's own airway bacteria can prevent ventilator-associated pneumonia (a lung infection from the breathing tube) in intensive care patients. It may help reduce infections in people who need a breathing tube for more than three days.
Hear when a new Anti-Bacterial Agents trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.